Liquid Biopsies最新文献

筛选
英文 中文
Abstract A21: High-throughput isolation of circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients for personalized treatments A21:高通量分离非小细胞肺癌(NSCLC)患者循环肿瘤细胞(CTCs)用于个性化治疗
Liquid Biopsies Pub Date : 2018-09-01 DOI: 10.1158/1557-3265.AACRIASLC18-A21
Mina Zeinali, Arthi Nadhan, A. Mathur, Maggie Lee, Wei Huang, M. Hafner, N. Ramnath, S. Nagrath
{"title":"Abstract A21: High-throughput isolation of circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients for personalized treatments","authors":"Mina Zeinali, Arthi Nadhan, A. Mathur, Maggie Lee, Wei Huang, M. Hafner, N. Ramnath, S. Nagrath","doi":"10.1158/1557-3265.AACRIASLC18-A21","DOIUrl":"https://doi.org/10.1158/1557-3265.AACRIASLC18-A21","url":null,"abstract":"It has been recognized that circulating tumor cells (CTCs) shed by a primary tumor can be a valuable surrogate to tissue biopsies. Our project goal is to develop a CTC-based liquid biopsy platform as a noninvasive method for identifying primary and secondary mutations in non-small lung cancer to direct personalized therapies. The high-throughput, label-free and size-based inertial microfluidic separation device “Labyrinth” developed in the Nagrath lab has been used for simultaneous isolation of epithelial (EpCs) and mesenchymal (EMTCs) CTCs from lung cancer patients. The total channel length of Labyrinth is 637 mm, with 500 mm in width and 100 mm in height. The device consists of complex of small and high ratio of curvature structures (11 long loops and sharp right-angle 56 corners) to enhance differential focusing of both CTCs and white blood cells into separate fluid streams in the outlet area. The high recoveries and advantage of size-based biomarker independent separation are crucial for the downstream applications including molecular characterization of CTCs (mutation and mRNA profiling) and expansion of CTCs in vitro. Labyrinth was optimized and tested for inertial separation of cancer cells using the human lung cancer cell line PC-9. The percentage of recovery and purity was >93% with 2400 µL/min flow rate. We have enrolled 15 metastatic patients for this study and isolated CTCs from baseline (n=15) and post-therapy follow-up visits (range 1-4). To be able to detect different subpopulations of CTCs including EpCs and EMTCs from patients, we have employed immunofluorescence to label EpCAM (for EpCs) and Vim (for EMTCs), in addition to PanCK (tumor marker) and CD45 (leukocyte marker). CTCs were defined as EpCAM+/-/ Vim+/-/ PanCK+/ CD45-. All 15 patients, with different mutations/fusion, including EGFR, RET, ROS1, and ALK, had detectable CTCs at all visits, including 156±175 (at baseline, n=15), 141±133 (at visit 1, n=14), 255±218 (at visit 2, n=8), 84±81 (at visit 3, n=4), and 157±177 per mL (at visit 4, n=2). Patients with EGFR mutants had an average of 112±97 total CTCs per mL at their baseline and 66±57 after they were treated with either erlotinib or osimertanib. Patients with ROS1 fusion had slightly higher total CTCs per mL at their baseline (185±250) and during treatment with crizotinib (120±113) compared to EGFR mutant patients. To expand patient-derived CTCs for ex vivo drug testing, three different CTC culture conditions were tested: a plain, a “Fibronectin coated” (2D), and a “Matrigel-collagen-irradiated mice fibroblast coated” (3D) 48-well plate. After 6 weeks in culture, the growth rate was significantly higher in the 3D model. For CTC expansion, the enrichment methods require further optimization prior to adopting the 3D culture model for future samples. The cell surface marker independent microfluidic device, Labyrinth, isolated heterogeneous CTC subpopulations that were characterized and expanded in vitro. This could allow e","PeriodicalId":403370,"journal":{"name":"Liquid Biopsies","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121887289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract IA14: Circulating tumor DNA in early-stage NSCLC: A lung TRACERx study 摘要:早期NSCLC循环肿瘤DNA:肺TRACERx研究
Liquid Biopsies Pub Date : 2018-09-01 DOI: 10.1158/1557-3265.AACRIASLC18-IA14
C. Abbosh
{"title":"Abstract IA14: Circulating tumor DNA in early-stage NSCLC: A lung TRACERx study","authors":"C. Abbosh","doi":"10.1158/1557-3265.AACRIASLC18-IA14","DOIUrl":"https://doi.org/10.1158/1557-3265.AACRIASLC18-IA14","url":null,"abstract":"The Cancer Research UK-funded study TRACERx (TRAcking Cancer Evolution through therapy [Rx]) aims to recruit patients undergoing surgery for early-stage non-small cell lung cancer (NSCLC). Patients donate blood pre- and postoperatively alongside multi-region sampled primary tumor tissue. Up to 40% of patients undergoing surgery for NSCLC experience relapse of their disease. At this point patients are approached for relapse tissue sampling. TRACERx therefore provides a strong platform for evaluating circulating tumor DNA (ctDNA) in early-stage NSCLC and a minimal residual disease (MRD) setting. In this presentation we will describe data arising from a phylogenetic, patient-specific approach to ctDNA evaluation in the first 100 patients analyzed as part of TRACERx. We will discuss clinicopathologic factors associated with ctDNA detection in early-stage NSCLC and suggest the existence of distinct tumor phenotypic characteristics that predict the presence of ctDNA at measurable quantities in plasma. Additionally, we will discuss tumor volume limit of detection analyses and highlight potential implications of our findings within the context of early cancer detection. We will then examine data arising from the ctDNA profiling of postoperative plasma samples taken in the adjuvant setting. These data demonstrate that ctDNA detection is specific for NSCLC relapse and that ctDNA detection precedes clinical diagnosis of NSCLC relapse (median lead-time of 77 days, range 10 to 346 days). We will provide examples of using phylogenetic ctDNA profiling to characterize the subclonal nature of relapsing NSCLC as a potential method to personalize relapse therapeutic intervention. Finally, we will highlight potential advantages of patient-specific ctDNA profiling in an adjuvant MRD setting and suggest ways that this technology can be used to fuel adjuvant drug development in NSCLC by driving novel study designs. Citation Format: Christopher Abbosh. Circulating tumor DNA in early-stage NSCLC: A lung TRACERx study [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr IA14.","PeriodicalId":403370,"journal":{"name":"Liquid Biopsies","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130024865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract A22: Establishing a deep cfDNA methylation sequencing-based signature for noninvasive early-stage lung cancer diagnosis A22:建立基于深度cfDNA甲基化测序的无创早期肺癌诊断特征
Liquid Biopsies Pub Date : 2018-09-01 DOI: 10.1158/1557-3265.AACRIASLC18-A22
Zhihong Zhang, N. Liang, W. Deng, Chenyang Wang, Tao Zheng, Wenjun Li, Jian Hu, J. Su, H. Han‐Zhang, Bingsi Li, Hao Liu, Shanqing Li
{"title":"Abstract A22: Establishing a deep cfDNA methylation sequencing-based signature for noninvasive early-stage lung cancer diagnosis","authors":"Zhihong Zhang, N. Liang, W. Deng, Chenyang Wang, Tao Zheng, Wenjun Li, Jian Hu, J. Su, H. Han‐Zhang, Bingsi Li, Hao Liu, Shanqing Li","doi":"10.1158/1557-3265.AACRIASLC18-A22","DOIUrl":"https://doi.org/10.1158/1557-3265.AACRIASLC18-A22","url":null,"abstract":"Although mortality rate has been greatly reduced by low-dose computed tomography (LDCT) screening of high-risk patients, the benefit is compromised by the high false-positive rate, thus necessitating the development of biomarkers differentiating benign and malignant nodules. The role of aberrant DNA methylation in the process of tumorigenesis both at individual genes and a genome-wide scale has been well elucidated. It occurs very early in cancer development, and thus is capable of serving as a diagnostic biomarker. In this prospective study, we evaluated the feasibility and performance of assessing cfDNA methylation status as an early diagnostic marker for lung cancer. We developed a novel targeted bisulfite sequencing assay called ELSA and designed a methylation panel based on TCGA data on 838 lung cancer patients and 74 normal controls. We then interrogated the methylation status of 7,572 regions consisting of about 100,000 CpG sites from plasma samples of 163 newly recruited Chinese patients with early-stage NSCLC and 41 with benign nodules using our panel. A region-based methylation statistic was used in the classification model. We constructed diagnostic classification models using elastic net and random forest based on 3,000 DMRs selected by logistic regression between benign and malignant nodules using FFPE samples. Within this cohort, 54 patients had malignant tumor (39 stage I, 6 stage II and 9 stage IIIa) and 30 patients had benign nodules. We performed 5-fold cross-validation with 20 time repeats to gain a robust estimation of model performance, achieving a sensitivity of 92.6%, specificity of 100% and AUC of 98.1%. We further refined the DMRs selected above using 68 healthy baseline plasmas, and subsequently constructed a weighting decision tree model for plasma samples obtained from a separate cohort consisting of 163 patients with malignant tumor (127 stage I, 36 stage II and above) and 41 patients with hamartoma, chronic inflammation, granuloma, or other lung benign lesions, achieving a sensitivity of 84.0%, specificity of 85.7% and AUC of 90.7% based on 170 markers. We further analyzed PPVs according to stage and tumor size. PPVs for patients with stage I, II, and III diseases are 82.4%, 84.6%, and 94.4%, respectively; and for tumor diameter less than 1 cm, between 1-2 cm, and greater than 2 cm are 78.5%, 87.1%, and 88.2%, respectively. Citation Format: Zhihong Zhang, Naixin Liang, Wanglong Deng, Chenyang Wang, Tao Zheng, Wenjun Li, Jian Hu, Jinh Su, Han Han-Zhang, Bingsi Li, Hao Liu, Shanqing Li. Establishing a deep cfDNA methylation sequencing-based signature for noninvasive early-stage lung cancer diagnosis [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr A22.","PeriodicalId":403370,"journal":{"name":"Liquid Biopsies","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117123493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract A18: Diagnostic and prognostic utility of urinary creatine riboside for early stage non-small cell lung cancer 摘要A18:尿肌酸核苷对早期非小细胞肺癌的诊断和预后价值
Liquid Biopsies Pub Date : 2018-09-01 DOI: 10.1158/1557-3265.aacriaslc18-a18
T. Oike, Y. Kanke, Amelia L. Parker, M. Haznadar, K. Krausz, E. Bowman, A. Robles, F. J. González, C. Harris
{"title":"Abstract A18: Diagnostic and prognostic utility of urinary creatine riboside for early stage non-small cell lung cancer","authors":"T. Oike, Y. Kanke, Amelia L. Parker, M. Haznadar, K. Krausz, E. Bowman, A. Robles, F. J. González, C. Harris","doi":"10.1158/1557-3265.aacriaslc18-a18","DOIUrl":"https://doi.org/10.1158/1557-3265.aacriaslc18-a18","url":null,"abstract":"","PeriodicalId":403370,"journal":{"name":"Liquid Biopsies","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126912351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Abstract PR04: Decoding tumor microenvironment to enhance NSCLC targeted therapy PR04:解码肿瘤微环境增强NSCLC靶向治疗
Liquid Biopsies Pub Date : 2018-09-01 DOI: 10.1158/1557-3265.AACRIASLC18-PR04
Haichuan Hu, L. Sequist, Z. Piotrowska, Hillary E. Mulvey, Sundus Noeen, Patricia J. Hare, D. Kodack, A. Hata, M. Niederst, C. Benes, J. Engelman
{"title":"Abstract PR04: Decoding tumor microenvironment to enhance NSCLC targeted therapy","authors":"Haichuan Hu, L. Sequist, Z. Piotrowska, Hillary E. Mulvey, Sundus Noeen, Patricia J. Hare, D. Kodack, A. Hata, M. Niederst, C. Benes, J. Engelman","doi":"10.1158/1557-3265.AACRIASLC18-PR04","DOIUrl":"https://doi.org/10.1158/1557-3265.AACRIASLC18-PR04","url":null,"abstract":"Background: Tyrosine kinase inhibitors (TKI) have yielded promising responses in non-small cell lung cancer (NSCLC) with EGFR mutations and ALK translocations. However, these and other targeted therapies are limited by intrinsic and acquired drug resistance. The previous study from our group investigated tumor autonomous resistance mechanisms by developing patient-derived cancer models (PDCs). In this study, we aimed to decipher the nonautonomous resistance mechanisms via tumor microenvironment by developing patient-derived fibroblast (PDF) models. Method: Cancer-associated fibroblast cell lines are established directly from individual EGFR mutant NSCLC biopsies. These cell lines, as representative of each patient’s tumor microenvironment, are further subjected to functional analysis. An imaging-based high-throughput platform is developed to screen for nonautonomous resistance by co-culturing PDC and PDF models in vitro. In the parallel, two independent approaches are performed to further identify mechanisms underlying the nonautonomous resistance. These include a drug screen to determine the pathway maintaining the cancer cells’ survival, and a secretomic analysis on the PDFs to identify the plausible cytokine(s) responsible for the resistance. Result: By co-culturing screening, nonautonomous resistance can be found in a wide spectrum of models. The subsequent drug screen reveals both a canonical HGF-dependent and novel HGF-independent mechanisms contributing to EGFR TKI resistance. Both of these can be explained by the PDF’s variable cytokine secretion and can be overcome by specific therapeutic combinations. Moreover, the microenvironment-driven EGFR TKI resistance has also been validated in vivo. The prevalence of the identified cytokine is further tested in clinical specimens. Conclusion: PDFs provide a new avenue to explore nonautonomous resistance for targeted therapy. Applying this approach, we identified both the canonical HGF-dependent and novel HGF-independent mechanisms that putatively confer EGFR TKI resistance. Taking EGFR TKI therapy as a paradigm, these findings will be valuable to optimize targeted therapy and to inform the design of personalized pharmaceutical interventions. This abstract is also being presented as Poster B25. Citation Format: Haichuan Hu, Lecia Sequist, Zofia Piotrowska, Hillary Mulvey, Sundus Noeen, Patricia Hare, David Kodack, Aaron Hata, Matt Niederst, Cyril Benes, Jeff Engelman. Decoding tumor microenvironment to enhance NSCLC targeted therapy [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr PR04.","PeriodicalId":403370,"journal":{"name":"Liquid Biopsies","volume":"81 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131544246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract A20: Validation of the QuantStudio5 instrument for use in Biocept’s TargetSelectorTM ctDNA lung cancer assays qantstudio5仪器用于Biocept的TargetSelectorTM ctDNA肺癌检测的验证
Liquid Biopsies Pub Date : 2018-09-01 DOI: 10.1158/1557-3265.AACRIASLC18-A20
Shan-Fu Wu, J. Poole, T. Lu, Lyle J. Arnold, Jeffrey C. Chen, A. Pham, Veena Singh
{"title":"Abstract A20: Validation of the QuantStudio5 instrument for use in Biocept’s TargetSelectorTM ctDNA lung cancer assays","authors":"Shan-Fu Wu, J. Poole, T. Lu, Lyle J. Arnold, Jeffrey C. Chen, A. Pham, Veena Singh","doi":"10.1158/1557-3265.AACRIASLC18-A20","DOIUrl":"https://doi.org/10.1158/1557-3265.AACRIASLC18-A20","url":null,"abstract":"Background: Liquid biopsies represent a noninvasive alternative to traditional tissue biopsies, enabling the detection and tracking of cancer driver mutations from a simple blood draw. Biocept’s Target SelectorTM test platform offers the unique ability to analyze biomarkers from both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). Here we performed a clinical concordance study, comparing the ABI 7900 to the newer ABI QuantStudio 5 (QS5) for integration of the QS5 into Biocept’s CAP/CLIA certified laboratory. TargetSelectorTM ctDNA mutation tests were validated for five targets, including EGFR (Del19, L858R, or T790M), BRAF, and KRAS, all markers integral to devising personalized therapies for non-small cell lung cancer (NSCLC) patients. Methods: Prior to assessing clinical samples, extensive analytical validation was performed with DNA extracted from cancer cell lines containing the relevant EGFR, BRAF or KRAS mutations. TargetSelectorTM ctDNA mutant assays procedurally incorporate real-time PCR and DNA sequencing. The analytical validation was conducted to compare the performance of the ABI 7900 vs QS5 instruments within Biocept’s ctDNA testing platform. Evaluation of 3000 samples across the five TargetSelectorTM assays demonstrated single mutant copy detection sensitivity on the QS5 platform, with >99% sensitivity and >99% specificity for each of the ctDNA mutant assays. Following analytical evaluation, synchronized aliquots of 13 patient ctDNA samples, extracted from whole blood collected in Biocept CEE-SureTM Blood Collection tubes, were used to test the performance of both the ABI 7900 and QS5 instruments in the TargetSelectorTM ctDNA assays. Results: EGFR, BRAF and KRAS TargetSelectorTM assays that incorporate the ABI QS5 vs the ABI 7900 enable more sensitive ctDNA testing, as demonstrated by analytical validation and subsequent analyses of clinical samples. In patient samples, TargetSelectorTM tests using the QS5 identified all of the mutations detected by same assays on the ABI 7900 platform. Utilization of the QS5 instrument within the TargetSelectorTM also enabled identification of additional mutations not detected in the assays where the ABI 7900 was used. Conclusions: Implementation of the QuantStudio 5 real-time PCR instrument into Biocept’s TargetSelectorTM ctDNA assays has improved performance over the older TargetSelectorTM platform that utilized the ABI 7900. The more sensitive QS5-based TargetSelectorTM assays increase the likelihood of identifying molecular drivers linked to a patient’s cancer. Liquid biopsy detection of EGFR, BRAF and KRAS mutant ctDNA provides a minimally invasive means to gain valuable information towards developing personalized treatment strategies, monitoring therapeutic response, and identifying potential resistance mechanisms, all of which are vital for disease management and NSCLC patient care. Citation Format: Shan Fu Wu, Jason C. Poole, Tim T. Lu, Lyle J. Arnold, Jeffrey Chen, Anh Ph","PeriodicalId":403370,"journal":{"name":"Liquid Biopsies","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132342948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liquid Biopsies: Methods and Protocols 液体活检:方法和方案
Liquid Biopsies Pub Date : 1900-01-01 DOI: 10.1007/978-1-0716-3346-5
{"title":"Liquid Biopsies: Methods and Protocols","authors":"","doi":"10.1007/978-1-0716-3346-5","DOIUrl":"https://doi.org/10.1007/978-1-0716-3346-5","url":null,"abstract":"","PeriodicalId":403370,"journal":{"name":"Liquid Biopsies","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131362931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书